Navigation Links
Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
Date:12/8/2010

ness about Novel Technologies 18

3.2.5 Cumbersome and Lengthy Development Procedure Discourages Biomarker Research by the Pharmaceutical Sector 18

4 Personalized Medicine Market – Personalized Therapeutics and Diagnostics 19

4.1 Personalized Therapeutics – Drug Profiles 19

4.1.1 Herceptin (trastuzumab) 19

4.1.2 Erbitux (cetuximab) 24

4.1.3 Gleevec (imatinib) 28

4.1.4 Zyprexa (olazapine) 32

4.1.5 Lipitor (atorvastatin) 35

4.1.6 Celebrex (celecoxib) 39

4.1.7 Tarceva (erlotinib) 42

4.1.8 Rituxan (rituximab) 46

4.1.9 Plavix (clopidogrel bisulfate) 49

4.1.10 Risperdal (risperidone) 51

4.1.11 Vectibix (Panitumumab) 54

4.1.12 Coumadin (Warfarin) 56

4.1.13 Iressa (Gefitinib) 57

4.1.14 Sprycel 59

4.1.15 Camptosar 61

4.2 Companion Diagnostics 62

4.2.1 Selected Companion Diagnostics Employed in Personalized Healthcare 64

4.3 Biomarkers 67

4.3.1 Biomarkers in Cancer Research 68

4.3.2 Market Size and Forecasts 69

4.3.3 Segmentation by Indication 70

5 Personalized Medicine Market: Selected Pipeline Product Profiles 80

5.1 PF-4948568 (Pfizer) 80

5.1.1 Overview 80

5.1.2 Mechanism of Action 80

5.1.3 Clinical Study Details 80

5.2 PF-02341066 + Erlotinib (Pfizer) 81

5.2.1 Overview 81

5.2.2 Mechanism of Action 81

5.2.3 Clinical study details 81

5.3 PF-299804 (Pfizer) 82

5.3.1 Overview 82

5.3.2 Mechanism of action 82

5.3.3 Clinical study details 82

5.4 CEP-701 (Cephalon Inc.) 83

5.4.1 Overview 83

5.4.2 Mechanism of action 83

5.4.3 Clinical study details 84

5.5 TBR-652 (Tobira Therapeutics, Inc) 84

5.5.1 Overview 84

5.5.2 Mechanism of action 84

5.5.3 Clinical study details 85

5.6 Brivanib (Bristol-Myers Squibb) 85

5.6.1 Overview 85

5.6.2 Mechanis
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology news :

1. Reportlinker Adds Global Flow Cytometers Industry
2. Reportlinker Adds World Biometrics Market
3. Reportlinker Adds Global Biometrics Industry
4. Reportlinker Adds Biomarkers - technologies, markets and companies
5. Reportlinker Adds Proteomics: Technologies and Global Markets Report
6. Reportlinker Adds World Dynamic Signature Verification Market Report
7. Reportlinker Adds Carbon Dioxide Monitors Report
8. Personalized diets for elderly after hospitalization decreases mortality rates
9. OGI invests in personalized medicine for age-related macular degeneration
10. AACR congratulates William S. Dalton on 2010 Leadership in Personalized Medicine Award
11. With growing US support for personalized medicine, a look at ethical dilemmas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... numbers have decreased by 45% on average over a ... reports a study on the impact of humans on ... enormous benefits invertebrates such as insects, spiders, crustaceans, slugs ... and pest control for crops, decomposition for nutrient cycling, ... in Science and led by UCL, Stanford ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... abnormalities like hypertension, obesity, insulin resistance, and excess ... disease and diabetes. Individuals with a genetic predisposition ... be especially vulnerable to metabolic syndrome, but researchers ... desaturase-1 (SCD1), which helps synthesize unsaturated fatty acids, ...
... have identified the gene that sets off a sequence ... adults that can lead to high blood pressure. The ... the creation of blockages that can cause heart attacks, ... a study led by Ohio State University researchers might ...
... the western world, but new therapies based on stem cells ... held back however by the difficulty testing new therapies on ... value owing to differences in structure and activity. The only ... create computerised in-silico models that simulate the real heart and ...
Cached Biology News:High blood pressure in older adults traced to gene's effects in blood vessels 2High blood pressure in older adults traced to gene's effects in blood vessels 3The construction of heart modelling leads path to new therapies 2The construction of heart modelling leads path to new therapies 3
(Date:7/24/2014)... -- Research and Markets has announced the ... Instruments Market 2014-2018" report to their offering. ... is the study of the gene and its functions ... functions of proteomes or sets of proteins by using ... the mapping of genes and DNA sequencing to understand ...
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... 24, 2014  Neogen Corporation (Nasdaq: NEOG ... its potential revenue from new rodenticide research are premature. ... analysts on July 22, 2014, Neogen,s CEO commented about ... research. "It was my intent Tuesday at ... of a new type of rodenticide, but certainly not ...
(Date:7/24/2014)... Toronto, Canada (PRWEB) July 24, 2014 ... for Optimizing Dose Escalation in First in Human Studies” ... to make better go/no-go decisions. , With increasing R&D ... market, pharmaceutical companies need to maximize the knowledge collected ... go/no-go decisions and improve success in late stage development. ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... workforce reduction, NEW YORK, April 4, 2008 ... that it is implementing a,strategic restructuring plan to ... efforts. The plan, which was prompted by the ... clinical trial of Sulonex(TM),(sulodexide) for the treatment of ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... that the first New Zealand patient,was treated with ... December 2007. A second patient was treated in ... drug-eluting stent for peripheral,arterial disease (PAD) and was ...
... held at the Society for Biomolecular Sciences 14th ... ... Ltd., an,international provider of microfluidic systems in the emerging field of,nano-lifesciences, ... enables researchers to execute physiologically,relevant flow experiments evaluating the adhesion of ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 2Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 3Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 4Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays 2
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
... Rabbit polyclonal to Kv4.2 Immunogen ... corresponding to amino acids 23-43 of Rat ... with Rat.Expected to cross-react with Human (100% ... immunogen), Rabbit (100% identity with immunogen) and ...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Cryo/CryoPlus Inventory Racks for ... available with cardboard or stainless ... or 5ml cryo vials. ... racks available. Platform risers ...
Biology Products: